557 related articles for article (PubMed ID: 26299615)
1. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
Di Paolo D; Yang D; Pastorino F; Emionite L; Cilli M; Daga A; Destafanis E; Di Fiore A; Piaggio F; Brignole C; Xu X; Liang C; Gibbons J; Ponzoni M; Perri P
Oncotarget; 2015 Oct; 6(30):28774-89. PubMed ID: 26299615
[TBL] [Abstract][Full Text] [Related]
2. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
[TBL] [Abstract][Full Text] [Related]
3. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.
Wang Y; Wang L; Guan S; Cao W; Wang H; Chen Z; Zhao Y; Yu Y; Zhang H; Pang JC; Huang SL; Akiyama Y; Yang Y; Sun W; Xu X; Shi Y; Zhang H; Kim ES; Muscal JA; Lu F; Yang J
Sci Rep; 2016 Jan; 6():19423. PubMed ID: 26786851
[TBL] [Abstract][Full Text] [Related]
4. Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma.
Di Paolo D; Ambrogio C; Pastorino F; Brignole C; Martinengo C; Carosio R; Loi M; Pagnan G; Emionite L; Cilli M; Ribatti D; Allen TM; Chiarle R; Ponzoni M; Perri P
Mol Ther; 2011 Dec; 19(12):2201-12. PubMed ID: 21829174
[TBL] [Abstract][Full Text] [Related]
5. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
[TBL] [Abstract][Full Text] [Related]
6. Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK.
Di Paolo D; Brignole C; Pastorino F; Carosio R; Zorzoli A; Rossi M; Loi M; Pagnan G; Emionite L; Cilli M; Bruno S; Chiarle R; Allen TM; Ponzoni M; Perri P
Mol Ther; 2011 Jun; 19(6):1131-40. PubMed ID: 21487394
[TBL] [Abstract][Full Text] [Related]
7. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
[TBL] [Abstract][Full Text] [Related]
8. Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.
Siaw JT; Wan H; Pfeifer K; Rivera VM; Guan J; Palmer RH; Hallberg B
Oncotarget; 2016 May; 7(20):29011-22. PubMed ID: 27049722
[TBL] [Abstract][Full Text] [Related]
9. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
Mori M; Ueno Y; Konagai S; Fushiki H; Shimada I; Kondoh Y; Saito R; Mori K; Shindou N; Soga T; Sakagami H; Furutani T; Doihara H; Kudoh M; Kuromitsu S
Mol Cancer Ther; 2014 Feb; 13(2):329-40. PubMed ID: 24419060
[TBL] [Abstract][Full Text] [Related]
10. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.
Iyer R; Wehrmann L; Golden RL; Naraparaju K; Croucher JL; MacFarland SP; Guan P; Kolla V; Wei G; Cam N; Li G; Hornby Z; Brodeur GM
Cancer Lett; 2016 Mar; 372(2):179-86. PubMed ID: 26797418
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma.
Xu F; Li H; Sun Y
Biochem Biophys Res Commun; 2014 Nov; 454(4):566-71. PubMed ID: 25450694
[TBL] [Abstract][Full Text] [Related]
12. The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.
Guan J; Tucker ER; Wan H; Chand D; Danielson LS; Ruuth K; El Wakil A; Witek B; Jamin Y; Umapathy G; Robinson SP; Johnson TW; Smeal T; Martinsson T; Chesler L; Palmer RH; Hallberg B
Dis Model Mech; 2016 Sep; 9(9):941-52. PubMed ID: 27483357
[TBL] [Abstract][Full Text] [Related]
13. ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT.
Debruyne DN; Bhatnagar N; Sharma B; Luther W; Moore NF; Cheung NK; Gray NS; George RE
Oncogene; 2016 Jul; 35(28):3681-91. PubMed ID: 26616860
[TBL] [Abstract][Full Text] [Related]
14. Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma.
Mitou G; Frentzel J; Desquesnes A; Le Gonidec S; AlSaati T; Beau I; Lamant L; Meggetto F; Espinos E; Codogno P; Brousset P; Giuriato S
Oncotarget; 2015 Oct; 6(30):30149-64. PubMed ID: 26338968
[TBL] [Abstract][Full Text] [Related]
15. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
Shen J; Najafi S; Stäble S; Fabian J; Koeneke E; Kolbinger FR; Wrobel JK; Meder B; Distel M; Heimburg T; Sippl W; Jung M; Peterziel H; Kranz D; Boutros M; Westermann F; Witt O; Oehme I
Cell Death Differ; 2018 Dec; 25(12):2053-2070. PubMed ID: 29515255
[TBL] [Abstract][Full Text] [Related]
16. Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma.
Redaelli S; Ceccon M; Antolini L; Rigolio R; Pirola A; Peronaci M; Gambacorti-Passerini C; Mologni L
Oncotarget; 2016 Nov; 7(45):72886-72897. PubMed ID: 27662658
[TBL] [Abstract][Full Text] [Related]
17. TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.
Croucher JL; Iyer R; Li N; Molteni V; Loren J; Gordon WP; Tuntland T; Liu B; Brodeur GM
Cancer Chemother Pharmacol; 2015 Jan; 75(1):131-41. PubMed ID: 25394774
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.
Yamazaki S; Lam JL; Zou HY; Wang H; Smeal T; Vicini P
Drug Metab Dispos; 2015 Jan; 43(1):54-62. PubMed ID: 25349124
[TBL] [Abstract][Full Text] [Related]
19. Dual
Wood AC; Krytska K; Ryles HT; Infarinato NR; Sano R; Hansel TD; Hart LS; King FJ; Smith TR; Ainscow E; Grandinetti KB; Tuntland T; Kim S; Caponigro G; He YQ; Krupa S; Li N; Harris JL; Mossé YP
Clin Cancer Res; 2017 Jun; 23(11):2856-2868. PubMed ID: 27986745
[No Abstract] [Full Text] [Related]
20. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.
Sakamoto H; Tsukaguchi T; Hiroshima S; Kodama T; Kobayashi T; Fukami TA; Oikawa N; Tsukuda T; Ishii N; Aoki Y
Cancer Cell; 2011 May; 19(5):679-90. PubMed ID: 21575866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]